Moderna Shares Soar on Success of Novel Melanoma Cancer Vaccine

Plus: Target’s second-quarter sales suggest the retailer’s turnaround is working. And Cantor Fitzgerald plans to give its hedge-fund clients access to Kalshi’s prediction markets. Alex Ossola hosts.

Sign up for WSJ’s free What’s News newsletter.

An artificial-intelligence tool assisted in the making of this episode by creating summaries that were based on Wall Street Journal reporting and reviewed and adapted by an editor.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.